BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22210682)

  • 1. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.
    Riolo G; Towheed TE
    J Rheumatol; 2012 Jan; 39(1):192-4. PubMed ID: 22210682
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 3. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 4. Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
    Brunasso AM; Scocco GL; Massone C
    J Rheumatol; 2010 Jul; 37(7):1549-50. PubMed ID: 20595297
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
    Dicaro D; Bowen C; Dalton SR
    J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
    Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.
    Hall HA; Zimmermann B
    Arthritis Rheum; 2006 Dec; 55(6):982-4. PubMed ID: 17139649
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.
    Nishimura K; Saegusa J; Kawano S; Morinobu A
    J Rheumatol; 2012 Sep; 39(9):1904-5. PubMed ID: 22942311
    [No Abstract]   [Full Text] [Related]  

  • 10. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching tumor necrosis factor alpha inhibitors in HLA-B27-associated severe heel enthesitis.
    Olivieri I; Scarano E; Padula A; D'angelo S; Cantini F
    Arthritis Rheum; 2007 Dec; 57(8):1572-4. PubMed ID: 18050233
    [No Abstract]   [Full Text] [Related]  

  • 12. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management.
    Papadavid E; Gazi S; Dalamaga M; Stavrianeas N; Ntelis V
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):380-2. PubMed ID: 18269613
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-induced lupus erythematosus in a patient treated with adalumimab.
    Spillane AP; Xia Y; Sniezek PJ
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 18. [Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb].
    van Rijthoven AW; van Roon JA
    Ned Tijdschr Geneeskd; 2007 Apr; 151(14):839; author reply 839. PubMed ID: 17469329
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab in juvenile rheumatoid arthritis.
    Sfriso P; Ravaioli F
    N Engl J Med; 2008 Dec; 359(23):2495; author reply 2496-7. PubMed ID: 19052133
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab in juvenile rheumatoid arthritis.
    Taddio A; Marchetti F
    N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.